
Soleno Therapeutics (SLNO) Stock Forecast & Price Target
Soleno Therapeutics (SLNO) Analyst Ratings
Bulls say
Soleno Therapeutics Inc. is showing a positive financial trajectory, with preliminary unaudited full-year 2025 net revenue reported at $190 million from the U.S. launch of VYKAT XR in 2Q25, significantly exceeding original forecasts. The company is in a robust financial position with an expected cash reserve of approximately $500 million by the end of 2025, demonstrating strong profitability and positive cash flow. Additionally, VYKAT XR has shown strong early adoption, evidenced by 1,250 new patient start forms and a 12% discontinuation rate in line with expectations, suggesting a solid future growth potential in the rare diseases therapeutics market.
Bears say
Soleno Therapeutics faces significant challenges related to the market access and reimbursement obstacles affecting the uptake of its product candidate DCCR, which could hinder revenue generation. Additionally, the potential for earlier-than-expected generic erosion of the DCCR franchise, combined with difficulties in maximizing the product's value in international markets, raises concerns over the company's financial outlook. Risks are further compounded by the possibility of slower-than-anticipated U.S. commercialization progress, which may affect overall performance.
This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Soleno Therapeutics (SLNO) Analyst Forecast & Price Prediction
Start investing in Soleno Therapeutics (SLNO)
Order type
Buy in
Order amount
Est. shares
0 shares